Entering text into the input field will update the search result below

UBS upgrade lifts Celgene

Dec. 05, 2013 12:16 PM ETCelgene Corporation (CELG) StockCELGBy: Colin Lokey, SA News Editor
  • Shares of Celgene (CELG +3.3%) are moving notably higher in morning trading.
  • Likely behind the move is UBS, where analyst Matthew Roden has upgraded the stock to Buy from Neutral.
  • "We find CELG compares favorably to other names in healthcare and the broader markets on the basis of EPS growth (26% vs 16% HC and 13% S&P500), and operating margin (49% vs 13% and 16% in Q3 2013, and 60% achievable for CELG by 2017)," Roden notes.
  • Price target is $200.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
CELG--
Celgene Corporation